On July 20, 2026, endocrinologists in France discussed the clinical guidelines surrounding dual GIP and GLP-1 receptor agonists for metabolic wellness. Sourcing authentic treatments like Mounjaro (Tirzepatide) 2.5mg KwikPen has become a key interest for patients seeking weight management solutions under French clinical standards.

At Onco Medicine, we help bridge supply shortages by facilitating secure international delivery of original Tirzepatide formulations to France, complying with European health directives.

The Efficacy of GIP/GLP-1 Dual Agonists

• Dual-Action Hormone Regulation: Tirzepatide activates both GIP and GLP-1 pathways, resulting in superior glycemic control and body weight reduction compared to single-agent GLP-1 therapies.
• Weekly Dosing Convenience: The single-dose KwikPen design provides an easy, weekly self-injection routine that improves treatment compliance.
• Gradual Titration: Initiating with the 2.5mg dose minimizes gastrointestinal side effects and establishes tolerance before transitioning to higher maintenance doses.

Importing to France & ANSM Compliance

Sourcing personal medication from other European regions is guided by ANSM regulations. Onco Medicine manages the temperature-controlled packaging and customs clearance documentation, ensuring that every shipment is tracked and verified before arrival at your address in France.